Global influenza vaccine market to hit $14b by 2032

Developments include cell-based and recombinant DNA technologies.

The global influenza vaccine market is projected to cross $14b by 2032, according to DelveInsight.

The sector’s expansion is attributed to the increasing prevalence of influenza and rising vaccination uptake.

Developments in vaccine production include a shift from traditional egg-based methods to cell-based and recombinant DNA technologies.

“The emergence of mRNA vaccines, as seen in the COVID-19 pandemic, has introduced a new era of possibilities for influenza vaccines, promising better efficacy and faster production timelines,” the report said.